{"id":325852,"date":"2022-05-09T09:58:25","date_gmt":"2022-05-09T07:58:25","guid":{"rendered":"https:\/\/medizinonline.com\/evolocumab-stabilizes-plaques-in-90-of-patients-with-acute-coronary-syndrome\/"},"modified":"2022-05-09T09:58:25","modified_gmt":"2022-05-09T07:58:25","slug":"evolocumab-stabilizes-plaques-in-90-of-patients-with-acute-coronary-syndrome","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/evolocumab-stabilizes-plaques-in-90-of-patients-with-acute-coronary-syndrome\/","title":{"rendered":"Evolocumab stabilizes plaques in 90% of patients with acute coronary syndrome"},"content":{"rendered":"<p><strong><span style=\"color:windowtext\">After an acute coronary syndrome, patients are at high risk for further cardiovascular disease. Atherosclerotic plaques play a crucial role in this process, as up to 75% of acute coronary syndrome episodes are triggered by plaque rupture. It is already known that a low LDL-C level may contribute to plaque stabilization. The HUYGENS study has now been able to show,&nbsp;<\/span><\/strong><strong><span style=\"color:windowtext\">that the early addition&nbsp;<\/span><\/strong><strong><span style=\"color:windowtext\">of the PCSK9 inhibitor evolocumab to statin therapy after acute coronary syndrome is well tolerated and contributes to the stabilization of vulnerable plaques1<\/span><span style=\"color:windowtext\">. This underscores the relevance of early use of PCSK9 inhibitor for maximal LDL-C reduction in these high-risk cardiovascular patients.<\/span><\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>In the following video, PD Dr. med. Gregor Leibundgut, Head of Cardiology at the Cantonal Hospital Baselland, presents the data of the HUYGENS study.<\/p>\n<p><iframe frameborder=\"0\" height=\"1080\" data-src=\"https:\/\/player.vimeo.com\/video\/708205738?h=454a8898ef&amp;badge=0&amp;autopause=0&amp;player_id=0&amp;app_id=58479\" title=\"HUYGENS_Leibundgut_final.mp4\" width=\"1920\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" data-load-mode=\"1\"><\/iframe><\/p>\n<p>&nbsp;<\/p>\n<p><strong>References:<\/strong><\/p>\n<div><span style=\"font-size:9px\">1. Nicholls, S.J., et al, Assessing the impact of PCSK9 inhibition on coronary plaque phenotype&nbsp;<\/span><span style=\"font-size:9px\">with optical coherence tomography: rationale and design of the randomized, placebo-controlled<\/span><\/div>\n<div><span style=\"font-size:9px\">HUYGENS study. Cardiovasc Diagn Ther, 2021. 11(1): p. 120 &#8211; 129.<\/span><\/div>\n<div>&nbsp;<\/div>\n<p>The latest technical information on Repatha<sup><span style=\"font-size:10px\"><span style=\"font-family:calibri,sans-serif\">\u00ae<\/span><\/span> <\/sup>can be found at <a href=\"http:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\">www.swissmedicinfo.ch.<\/a><\/p>\n<p>Post online since 10.05.2022<\/p>\n","protected":false},"excerpt":{"rendered":"<p>After an acute coronary syndrome, patients are at high risk for further cardiovascular disease. Atherosclerotic plaques play a crucial role in this process, as up to 75% of acute coronary&hellip;<\/p>\n","protected":false},"author":14,"featured_media":119676,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"High-risk cardiovascular patients.","footnotes":""},"category":[11334,11359,11384,11297,11548],"tags":[],"powerkit_post_featured":[],"class_list":["post-325852","post","type-post","status-publish","format-standard","has-post-thumbnail","category-angiology","category-cardiology","category-endocrinology-and-diabetology","category-general-internal-medicine","category-rx-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-25 00:52:22","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":325858,"slug":"levolocumab-stabilise-les-plaques-chez-90-des-patients-souffrant-dun-syndrome-coronarien-aigu","post_title":"L'\u00e9volocumab stabilise les plaques chez 90% des patients souffrant d'un syndrome coronarien aigu","href":"https:\/\/medizinonline.com\/fr\/levolocumab-stabilise-les-plaques-chez-90-des-patients-souffrant-dun-syndrome-coronarien-aigu\/"},"it_IT":{"locale":"it_IT","id":325864,"slug":"evolocumab-stabilizza-le-placche-nel-90-dei-pazienti-con-sindrome-coronarica-acuta","post_title":"Evolocumab stabilizza le placche nel 90% dei pazienti con sindrome coronarica acuta","href":"https:\/\/medizinonline.com\/it\/evolocumab-stabilizza-le-placche-nel-90-dei-pazienti-con-sindrome-coronarica-acuta\/"},"pt_PT":{"locale":"pt_PT","id":325869,"slug":"evolocumab-estabiliza-as-placas-em-90-dos-doentes-com-sindrome-coronaria-aguda","post_title":"Evolocumab estabiliza as placas em 90% dos doentes com s\u00edndrome coron\u00e1ria aguda","href":"https:\/\/medizinonline.com\/pt-pt\/evolocumab-estabiliza-as-placas-em-90-dos-doentes-com-sindrome-coronaria-aguda\/"},"es_ES":{"locale":"es_ES","id":325875,"slug":"evolocumab-estabiliza-las-placas-en-el-90-de-los-pacientes-con-sindrome-coronario-agudo","post_title":"Evolocumab estabiliza las placas en el 90% de los pacientes con s\u00edndrome coronario agudo","href":"https:\/\/medizinonline.com\/es\/evolocumab-estabiliza-las-placas-en-el-90-de-los-pacientes-con-sindrome-coronario-agudo\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/325852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=325852"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/325852\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/119676"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=325852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=325852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=325852"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=325852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}